Welcome to




The Rheumatology Division at the Children's Hospital at Montefiore (CHAM) is a national leader in children’s rheumatologic care and research. Our research focuses on novel therapies for children with chronic arthritis and systemic juvenile idiopathic arthritis. We also concentrate on atherosclerosis prevention in pediatric systemic lupus erythematosus and nonpharmacologic treatment of pain in childhood rheumatologic conditions. Our groundbreaking studies have helped to create new therapies that are revolutionizing the treatment of children and adolescents suffering from rheumatologic diseases and disorders. 

We are currently focused on research to:

Develop a National Registry to Track Outcomes of Pediatric Rheumatologic Diseases

Our investigators have established a comprehensive local disease registry to enable an in depth understanding of pediatric rheumatic diseases including systemic lupus erythematosus and juvenile dermatomyositis. Our team has also been fundamental in the establishment and ongoing data collection within the largest registry in the world for pediatric rheumatic diseases, such as juvenile idiopathic arthritis, childhood systemic lupus erythematosus, scleroderma and juvenile dermatomyositis. These registries have led to greater understanding of predictors of clinical outcomes in children with pediatric rheumatic diseases and has consequently helped healthcare workers to better tailor treatments for individual patients.  It has also enabled the collection of long-term safety surveillance data in patients on biologic therapies to better understand the risks of these therapies, such as infections.

Develop Novel Therapeutics

Our investigators have participated in numerous clinical trials using novel therapeutic agents in systemic lupus erythematosus and juvenile idiopathic arthritis in children have broadened the pharmacologic armamentarium to treat these diseases in patients who do not respond well enough to or who cannot tolerate treatment with conventional therapies.

Investigate the Impact of Mental Health on Outcomes in Pediatric Rheumatic Disease

Our physicians understand the complexity of rheumatologic diseases and the associated challenges surrounding chronic illnesses in children. Our team has developed novel methods of investigating psychosocial stressors in pediatric rheumatic disease and has engaged in numerous efforts to increase awareness regarding the impact of mental health on disease activity, treatment strategies and overall well-being.

Study the Risk of Cardiovascular Disease in Juvenile Dermatomyositis

CHAM investigators spearheaded the first study of children with juvenile dermatomyositis to look for early evidence of atherosclerosis (hardening of the arteries) before cardiovascular events occur.  This will enable the use of preventive measures in children and adolescents who are at higher risk for heart attacks and stroke.

Understand the Impact of COVID-19 on Children with Pediatric Rheumatic Disease

Our investigators have been on the forefront in the effort to understand the impact of COVID-19 on children with underlying rheumatic disease, both on and off immunosuppressive medications. Our team has developed a local registry to understand the impact of the pandemic on the care of our patients. Our experts have additionally led national efforts within the American College of Rheumatology to provide clinical guidance for the care of children with rheumatic disease. Our team has also collaborated closely with other medical teams to develop an understanding of Multisystem Inflammatory Syndrome in Children (MIS-C).




Active Clinical Trials

Trial Description
Disease / Condition
Principal Investigator
View all Clinical Trials